Title : Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C.

Pub. Date : 2004 Aug

PMID : 15232364






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. OBJECTIVES: Anemia is a common complication during interferon-ribavirin therapy for hepatitis C. While normally a fall in hematocrit in results in an exponential compensatory rise in erythropoietin, such that the correlation between hematocrit and erythropoietin is sharply negative, the erythropoietin response during interferon-ribavirin combination therapy is not known. Ribavirin erythropoietin Homo sapiens
2 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. OBJECTIVES: Anemia is a common complication during interferon-ribavirin therapy for hepatitis C. While normally a fall in hematocrit in results in an exponential compensatory rise in erythropoietin, such that the correlation between hematocrit and erythropoietin is sharply negative, the erythropoietin response during interferon-ribavirin combination therapy is not known. Ribavirin erythropoietin Homo sapiens
3 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. OBJECTIVES: Anemia is a common complication during interferon-ribavirin therapy for hepatitis C. While normally a fall in hematocrit in results in an exponential compensatory rise in erythropoietin, such that the correlation between hematocrit and erythropoietin is sharply negative, the erythropoietin response during interferon-ribavirin combination therapy is not known. Ribavirin erythropoietin Homo sapiens
4 There was an approximate 2 log10 reduction in maximal achievable erythropoietin level in subjects exposed to interferon-ribavirin combination. Ribavirin erythropoietin Homo sapiens
5 CONCLUSION: There is a subnormal rise of erythropoietin after interferon-ribavirin combination therapy for hepatitis C. Ribavirin erythropoietin Homo sapiens